Introduction
vomiting, Nausea
Nausea and vomiting are still perceived as major problems that result in substantial impairments in the patient’s functional activity and quality of life in patients receiving radiotherapy alone or with concomitant chemotherapy.Current guidelines suggest that patients undergoing radiotherapy and concomitant chemotherapy should receive antiemetic prophylaxis according to the guidelines for chemotherapy if the risk level of concomitant chemotherapy is higher than that of radiotherapy.Fosaprepitant is the prodrug of the NK-1RA aprepitant and can be rapidly converted to the active form after intravenous (IV) administration.